ArticleInfection and drug resistance2026
Impact of Drug-Resistant Tuberculosis Prevention and Control Strategies in Southeast China: Evidence from a Longitudinal Study on Disease Epidemic Trends and Predictions Across 15 Years.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite intensified efforts in drug-resistant tuberculosis control, the true burden and long-term trends of multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) remain unclear in many Asian settings. In China, where MDR/RR-TB accounts for a substantial share of global cases, regional variations in detection and reporting are pronounced. We aimed to examine changes in the burden and temporal trends of MDR/RR-TB in Zhejiang Province (2015-2023) and assess the impact of existing prevention and control measures. In addition, future incidence trends were projected to 2030 using an ARIMA model. Patients and methods: Individual-level MDR/RR-TB data from the Tuberculosis Information Management System were analyzed. Cases were estimated using the World Health Organization model. Temporal trends were assessed with Joinpoint regression, and future incidence was projected to 2030 using an autoregressive integrated moving average model. Results: Among 4,950 patients included, the detection rate increased from 24·55% in 2015 to 81·29% in 2023. Over the same period, the estimated MDR/RR-TB burden declined substantially (average annual percentage change: -17·20; 95% CI -20·89 to -14·36, p<0·0010), whereas notified cases increased initially and declined after 2018. The gap between estimated and notification cases narrowed markedly, indicating improved surveillance sensitivity. Substantial heterogeneity was observed across regions subgroups. Projections suggest a continued decline in incidence through 2030, although uncertainty increases over time. Conclusion: Strengthened surveillance and treatment strategies in Zhejiang Province have substantially reduced MDR/RR-TB burden and improved case detection, providing regionally relevant evidence for optimizing MDR/RR-TB control strategies in similar Asian settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.